3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Colorectal Neoplasms
4
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Tongue Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Salivary Gland Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-menopausal Breast Cancer
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
NVP-BKM120
×
Clear all
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts